Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform
BEIJING — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™ fully human antibody mouse platform has been granted an invention patent by the Japan Patent Office (JPO). This milestone marks a significant step in strengthening the global intellectual property portfolio of the RenMice ® fully human antibody platform family. It underscores the continued advancement of Biocytogen's comprehensive global patent strategy and highlights the innovation and international recognition of the company's proprietary technologies.
Article content
RenMab™ mice are a core member of Biocytogen's independently developed RenMice ® fully human antibody discovery platform family. Using Biocytogen's proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE ®) technology, the complete repertoire of murine immunoglobulin heavy chain and light chain variable region genes was precisely replaced in situ with their human counterparts. As a result, RenMab mice have the full repertoire of human antibody heavy chain VDJ and light chain VJ genes. It retains the ability to mount robust immune responses against diverse antigens, comparable to wild-type mice, and can generate fully human antibodies with native-like diversity, significantly improving the efficiency and success rate of discovering high-potential therapeutic candidates. Importantly, antibodies derived from RenMab mice require no additional humanization, effectively minimizing immunogenicity risks and streamlining the antibody drug development process.
Article content
With distinct advantages in discovering fully human antibodies and TCRs with low immunogenicity, high diversity, favorable affinity, and excellent physicochemical properties, Biocytogen's RenMice platform series (RenMab™/RenLite ® /RenNano ® /RenTCR-mimic™/RenTCR™) has gained widespread recognition in the global biotech and biopharmaceutical industry. Licensing agreements have been established with 20+ companies, including Merck KGaA, Darmstadt, Germany, Janssen/ Johnson & Johnson, and BeiGene. Leveraging the RenMice platform, the RenBiologics™ program has generated over 1,000,000 fully human antibody sequences and numerous high-potential preclinical candidates against more than 1,000 therapeutic targets. As of December 31, 2024, approximately 200 agreements encompassing therapeutic antibody co-development, out-licensing, and asset transfers have been executed, highlighting the RenMice platform's strong global competitiveness and significant commercial value.
Article content
With its sustained independent research and cutting-edge technological innovation capabilities, Biocytogen has been actively advancing its global patent portfolio and key technology protections for the RenMice ® platform. To date, the RenMice platform has secured patent grants in nearly 10 countries, including the U.S., China, and Japan, while nearly 40 patent applications are under examination across 15 countries and regions. With the steady progress of the global patent strategy, additional patent grants are anticipated in the near term. This strong intellectual property protection framework will continue to deliver reliable assurance to Biocytogen's partners worldwide.
Article content
About Biocytogen
Article content
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice ® (RenMab™/ RenLite ® / RenNano ® / RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice ® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
Article content
Article content
Article content
Contacts
Article content
Biocytogen Contacts
Article content
Article content
Antibody assets and platforms:
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
an hour ago
- CBC
Poilievre says 'Liberal government couldn't care less about the West' after canola tariffs
When asked about Prime Minister Mark Carney's response to China's 75 per cent tariff on Canadian canola, Conservative Leader Pierre Poilievre said the Liberal government disrespects western Canadian industries.
Globe and Mail
2 hours ago
- Globe and Mail
Citigroup Stock Surges 61.2% in a Year: Should You Buy It Now?
Citigroup, Inc. C shares have jumped 61.2% in the past year, outperforming the industry 's 46% rise. It also outpaced its close peers, Bank of America BAC and Wells Fargo 's WFC rises of 24% and 45.9%, respectively, over the same time frame. Price Performance Given such a strength in its share price, many investors are contemplating whether to add Citigroup stock to their portfolio now. Let us analyze the major factors at play to assess its investment appeal. Citigroup's Focus on Core Operations is Paying Off Citigroup has been focusing on growth in its core businesses by streamlining its overseas operations. In April 2021, the company announced its plan to exit the consumer banking business in 14 markets across Asia and EMEA. The company has exited from consumer banking businesses in nine countries. In May, C announced an agreement to sell its consumer banking business in Poland. In December 2024, Citigroup completed its separation of the institutional banking business in Mexico from its consumer, small, and middle market businesses, while in June 2024, it sold its China-based onshore consumer wealth portfolio. Additionally, as part of its strategy, Citigroup continues to make progress with the wind-down of its Korean consumer banking operations and its overall operations in Russia, as well as preparations for a planned initial public offering of its consumer banking and small business and middle-market banking operations in Mexico. These initiatives will free up capital and help the company pursue investments in wealth management and investment banking (IB) operations, which will stoke fee income growth. The company's efforts are already paying off as wealth management revenues registered a 22% year-over-year increase, while IB revenues rose 13% year over year in the first half of 2025. C expects revenues to grow, seeing a compounded annual rate of 4-5% by the end of 2026. C's Business Streamlining Efforts to Reduce Costs Citigroup has been emphasizing leaner, streamlined operations to reduce expenses. Pursuant to this, the company changed its operating model and the leadership structure. This resulted in a streamlined and straightforward management structure aligned with and supporting the bank's strategy of increased spans of control and significantly reduced bureaucracy and unnecessary complexity. In January 2024, C announced plans to cut 20,000 jobs or approximately 8% of its global staff by 2026. The bank had already made significant progress by reducing its headcount by more than 10,000 employees. The company also continues to focus on streamlining processes and platforms and driving automation to reduce manual touchpoints. Citigroup is increasingly deploying artificial intelligence (AI) tools to support these efforts. In the first half of 2025, the company's total expenses declined nearly 1% year over year. Management expects the 2025 expense to be $53.4 billion, slightly lower than $53.9 billion in 2024. Also, the company expects to achieve $2-2.5 billion of annualized run rate savings by 2026. Citigroup to Benefit From Fed Rate Cuts The Federal Reserve reduced interest rates by 100 basis points last year and has kept them steady since then. Given this, the company's net interest income (NII) is benefiting. In the first half of 2025, Citigroup's NII rose 8% year over year. Similarly, Bank of America's NII rose 4.9% year over year in the first half of 2025, while Wells Fargo's NII declined nearly 4% year over year. Although the Fed has kept interest rates unchanged this year amid tariff-related and inflationary pressures, the likelihood of a 25-basis-point cut at the September FOMC meeting has risen due to signs of labor market softness and tariff-driven inflation. This, along with strong growth in loans and deposit balances, will continue to support Citigroup's NII expansion. Following the announcement of the second-quarter results in July, management raised its projection for NII (ex-Markets) for 2025. The metric is expected to rise 4% on a year-over-year basis, up from the prior stated 2-3% rise. C's Strong Liquidity Aid Capital Distribution Citigroup enjoys a strong liquidity position. As of June 30, 2025, cash and due from banks and total investments aggregated to $474.4 billion, while its total debt (short-term and long-term borrowing) was $373.3 billion. Also, Citigroup's average Liquidity Coverage Ratio stood at 115% for the quarter ended June 30, 2025. Further, the common equity tier (CET) 1 capital ratio was 13.5% as of the same date. The company's focus on maintaining a strong capital base supports its capital distribution activities. Post-clearing the 2025 Fed stress test, the company hiked its dividend 7.1% to 60 cents per share. In the past five years, it has raised its dividends three times. It has a payout ratio of 33%. It has a dividend yield of 2.5% above the industry average of 1.9%. In January 2025, Citigroup's board of directors approved a $20-billion common stock repurchase program with no expiration date. As of June 30, 2025, $16.3 billion worth of authorization remained available. Supported by a strong capital and liquidity position, its capital distribution activities seem sustainable. Citigroup's Estimates & Valuation Analysis The Zacks Consensus Estimate for C's 2025 and 2026 sales implies year-over-year rallies of 4.2% and 3.1%, respectively. Sales Estimates Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 and 2026 earnings implies year-over-year increases of 27.4% and 27.7%, respectively. The estimates for both years have been revised upward over the past 30 days. Earnings Estimates From a valuation standpoint, C appears inexpensive relative to the industry. It is currently trading at a discount with a forward 12-month price-to-earnings (P/E) of 10.65X, well below the industry average of 14.48X. Price-to-Earnings F12M Further, Bank of America is trading at a 12-month forward P/E of 11.67X, while Wells Fargo is trading at 12.11X. Hence, C is trading at a discount compared with both. Should C Stock be Part of Your Portfolio? Citigroup's recent performance and strategic direction suggest that the bank is in the midst of a well-executed transformation that is already yielding results. Over the past year, the company has significantly outpaced its peers in share price growth, supported by decisive exits from underperforming markets, redirection of capital into high-return businesses, and a disciplined cost-reduction plan. The benefits from focus on sectors with attractive fee income potential are expected to compound through 2026. While risks remain, including economic uncertainty, credit quality pressures, and execution challenges tied to large-scale restructuring, Citigroup's combination of operational progress, revenue diversification, expense management, and shareholder-friendly capital deployment creates a favorable risk-reward profile. As such, investors can consider parking their cash in the C stock at the current level to generate a healthy long-term return. Citigroup currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bank of America Corporation (BAC): Free Stock Analysis Report Wells Fargo & Company (WFC): Free Stock Analysis Report Citigroup Inc. (C): Free Stock Analysis Report This article originally published on Zacks Investment Research (
CBC
2 hours ago
- CBC
Poilievre says B.C. Ferries loan to buy Chinese ships should be cancelled
Conservative Leader Pierre Poilievre says a $1-billion loan to B.C. Ferries should be cancelled after the provincial Crown corporation decided to work with a Chinese shipbuilder. Poilievre says China should be 'penalized' for its new tariffs on Canadian canola.
